Asked by: Jess Asato (Labour - Lowestoft)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the introduction of digital and AI tools in mental health care enhances rather than replaces the work of qualified counsellors and psychotherapists, in line with guidance from professional bodies such as the National Counselling and Psychotherapy Society.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
To deliver the shift from analogue to digital that is set out in the 10-Year Health Plan, we will create a digital front door for mental health care through the NHS App to boost access to early support and empower people to take steps to manage their symptoms.
Digital and artificial intelligence (AI) tools in mental health care can enhance and complement the work of qualified counsellors and psychotherapists, not replace human-delivered care. These tools can help with routine tasks like managing appointments, answering basic queries, updating clinical notes, and booking sessions. This means that clinicians can spend more time providing care to patients and patients have an improved experience across the care pathway, for example through reduced waiting times. Any new tools are introduced within a comprehensive regulatory framework in the National Health Service, underpinned by rigorous standards for safety, effectiveness, ethics, and data protection.
Publicly available AI applications that are not deployed by the NHS, such as ChatGPT and Character.AI, are not regulated as medical technologies and may offer incorrect or harmful information. Users are strongly advised to be careful when using these technologies.
Asked by: Ben Coleman (Labour - Chelsea and Fulham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of healthcare provision in prisons for inmates with diabetes; and what steps he is taking to ensure that diabetic prisoners have timely access to appropriate medical treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England commissions prison health care services into every prison in England. Every prison has onsite health care services including, primary care, mental health, dentistry, and substance misuse teams. This includes the care and management of those with long term conditions such as diabetes. All prisons offer a range of appointments to meet the needs of patients, and this includes routine appointments and urgent appointments.
NHS England commissions health care in prison that is the equivalence of community health care. The National Service Specification for primary care defines what this means for patients who require support. Access to health provision is available to every person in prison at any stage of their sentence, and this begins at the point of entry. NHS England also commissions health needs assessments across prisons to determine the needs and requirements of the prison population.
NHS England is reviewing the National Primary Care Service Specification to ensure it continues to meet the needs of the prison population.
Asked by: Ben Coleman (Labour - Chelsea and Fulham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of healthcare provision in prisons; and what steps he is taking to ensure that prisoners have timely access to appropriate medical treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England commissions prison health care services into every prison in England. Every prison has onsite health care services including, primary care, mental health, dentistry, and substance misuse teams. This includes the care and management of those with long term conditions such as diabetes. All prisons offer a range of appointments to meet the needs of patients, and this includes routine appointments and urgent appointments.
NHS England commissions health care in prison that is the equivalence of community health care. The National Service Specification for primary care defines what this means for patients who require support. Access to health provision is available to every person in prison at any stage of their sentence, and this begins at the point of entry. NHS England also commissions health needs assessments across prisons to determine the needs and requirements of the prison population.
NHS England is reviewing the National Primary Care Service Specification to ensure it continues to meet the needs of the prison population.
Asked by: Jen Craft (Labour - Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made for the potential implications for his policies of the BSL Advisory Board report on Health and Social Care, published on 27 November 2025.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards are responsible for commissioning services to meet the health needs of their local population, which includes responsibility for ensuring that there is adequate provision of British Sign Language (BSL) interpreters to support deaf patients in the community.
We welcome the British Sign Language Advisory Board’s report titled Locked out: Exclusion of deaf and deafblind BSL users from health and social care in the UK. We will carefully consider its recommendations, including how, in the context of our work on the 10-Year Health Plan and reform of adult social care, we can improve the experiences of Deaf people when accessing health and care services and experience of Deaf people.
Asked by: Peter Swallow (Labour - Bracknell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve patient experience of the NHS App.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS App is at the forefront of a major digital transformation and will revolutionise access to healthcare by putting patients at the centre of a modern, personalised, and data-driven service. One of the key aims is to empower individuals with greater choice, transparency, and control over their care.
The NHS App is co-designed with patients from a wide range of background and needs, with 14,000 users involved in user research in 2025 alongside 42,000 survey completions. Our research teams also have a rule of always doing rounds of research with often excluded or disadvantaged groups. This is often facilitated by partners like the Royal National Institute of Blind People and Mencap who help us to involve the appropriate people.
The NHS App is already helping people manage their health more easily, whether that’s viewing records, booking appointments, ordering prescriptions, or accessing test results. In the past year alone, the app has sent over 181 million messages, supported over 32 million vaccination invites, and offered more than 16 million vaccination appointments, many in local pharmacies. These numbers show how the app is not just supporting care but actively shifting it closer to home.
By 2030, patients will be able to manage their care remotely, contribute to their health records, and navigate the system with confidence, driving better outcomes and a more integrated, responsive National Health Service.
Asked by: Ben Goldsborough (Labour - South Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to (a) alter and (b) mitigate the National Institute for Care and Excellence's downgrading of terminal cancer to moderately severe.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not classified terminal cancer as moderately severe. The NICE is an independent body and is responsible for developing the methods and processes it uses to evaluate whether new medicines should be recommended for routine National Health Service funding.
In developing recommendations on whether medicines represent a clinically and cost effective use of NHS resources, NICE is able to apply a weighting that recognises the additional value that society places on treatments for severe conditions. The weighting that is applied is calculated for each appraisal based on information on the expected shortfall in life expectancy and quality of life of people with the condition taking into account existing treatment options. NICE has concluded for several appraisals of medicines for advanced cancer that a weighting should be applied based on the severity of the condition. The latest data for appraisals published up to September 2025, show that NICE has recommended 84.8% of treatments for advanced cancers since the severity modifier was introduced compared to 69.1% under its previous methods.
NICE is monitoring the impact of the changes made following the methods review and has committed to considering modular updates to its methods and processes in the future. NICE has also commissioned research to gather further evidence on societal preferences that will inform future methods reviews.
Asked by: Sarah Owen (Labour - Luton North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many (a) breast implants and (b) PIP breast implants have ruptured and had to be removed in the last 10 years; and how many of those ruptured implants were not listed on the breast and cosmetic implant registry when implanted.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Breast and Cosmetic Implant Registry (BCIR), set up in 2016, collects all implant data, and explant data where possible.
Practically, it is always difficult and often impossible to identify a model and product code on an explant. If explanted devices, or patients undergoing explant, cannot be linked to data collected at time of implant, then this often reduces explant data to 'patient, surgeon, location, date'. This in turn makes it impossible to monitor trends in explant/failure.
NHS England is in the process of clarifying and mandating the detail required in the BCIR and other device-related collections.
This will place a greater responsibility on trusts to either identify a device at the point of explant, or to identify the device from internal trust records created during the same patient's implant procedure. This will only be possible if the implant and explant are performed at the same trust. It is then the intention of NHS England to provide the same matching service for implant/explant where the trusts differ.
This solution will, when implemented, give a full, proactive picture of device longevity/risk, for the purposes of research and surveillance, alongside the existing ability to identify patients affected by a device recall notice.
Asked by: Sarah Owen (Labour - Luton North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many women in the UK have received Allergan breast implants.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Breast and Cosmetic Implant Registry (BCIR), set up in 2016, collects all implant data, and explant data where possible.
Practically, it is always difficult and often impossible to identify a model and product code on an explant. If explanted devices, or patients undergoing explant, cannot be linked to data collected at time of implant, then this often reduces explant data to 'patient, surgeon, location, date'. This in turn makes it impossible to monitor trends in explant/failure.
NHS England is in the process of clarifying and mandating the detail required in the BCIR and other device-related collections.
This will place a greater responsibility on trusts to either identify a device at the point of explant, or to identify the device from internal trust records created during the same patient's implant procedure. This will only be possible if the implant and explant are performed at the same trust. It is then the intention of NHS England to provide the same matching service for implant/explant where the trusts differ.
This solution will, when implemented, give a full, proactive picture of device longevity/risk, for the purposes of research and surveillance, alongside the existing ability to identify patients affected by a device recall notice.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has reviewed the rate of uptake of biologic medicines for severe asthma relative to the eligible population.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not conducted any such review, but this information is available via the NHS England Innovation Scorecard, which is published bi-annually.
Across all disease areas, though the 10-Year Health Plan and the Life Sciences Sector Plan, the Government has commitment to reducing friction in the system to optimise access and uptake of new medicines so the most clinically and cost-effective can reach patients faster. These actions will speed up market access for new medicines and reduce local unwarranted variation in medicine use.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of (a) trends in the level of variation in access to NICE-recommended biologic medicines for severe asthma.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made. NHS England is working with the health innovation networks and has formed the Respiratory Transformation Partnership. Focusing on improving the outcomes of people living with asthma and chronic obstructive pulmonary disease (COPD), this programme seeks to find scalable ways to decrease premature mortality and bed occupancy from respiratory diseases. Initiatives will seek to improve disease recognition, optimise delivery of National Institute for Health and Care Excellence (NICE) approved approaches at neighbourhood level, and uptake of existing and emerging biologic therapies.
The current NHS England severe asthma service specification is being revised by the Specialised Respiratory Clinical Reference Group. The current service specification is available at the following link:
The revised specification will support the management of patients who require further investigation and treatments including biological medicines. The specification will also be updated to reference the most recent clinical guidelines such as the British Thoracic Society, NICE, and the Scottish Intercollegiate Guidelines Network asthma guideline covering diagnosing, monitoring, and managing asthma in adults, young people, and children, and which is expected to improve outcomes for people with asthma and identify early those who require further investigation and treatments including biologic medicines. This guideline is available at the following link:
https://www.nice.org.uk/guidance/ng245